FOLH1 and neoplasm: Monoclonal antibodies targeting PSMA can be radiolabeled with specific radionuclides that are chosen for particular tumor characteristics and clinical indications, whether it be for targeted radiodiagnosis or systemic radiotherapy, and may serve as an alternative or have a complementary role to PSMA small molecule radioligands.